Organogenesis

What Organogenesis does

Organogenesis Inc. is a publicly traded regenerative medicine company (NASDAQ: ORGO) founded in 1985 as an MIT spin-off, headquartered in Canton, Massachusetts. The company develops and commercializes bioactive and acellular biomaterials, extracellular-matrix scaffolds, skin substitutes, and cryopreserved amniotic suspension allografts for advanced wound care, surgical, and sports medicine applications. Its portfolio includes FDA PMA-approved Apligraf for venous leg ulcers (1998) and diabetic foot ulcers (2000), the PuraPly antimicrobial wound matrix line, Dermagraft (acquired 2014), NuTech Medical products (acquired 2017), and the pipeline candidate ReNu for knee osteoarthritis (BLA submission completed April 2026).

Organogenesis sells primarily through a direct U.S. commercial sales organization established in 2004, targeting wound care clinicians, surgeons, and health systems across acute care, outpatient, and physician office settings, supplemented by a European commercial office in Switzerland (since 2006). The company also operates in-house biomanufacturing facilities in Canton and Norwood, Massachusetts, and announced a new state-of-the-art facility in Smithfield, Rhode Island in May 2025 with a $100 million investment. Revenue is generated via one-time product sales of advanced wound care and surgical biologics, supported by reimbursement specialists and a customer care center.

FY2025 revenue reached $563.0 million (up 17% YoY) with adjusted EBITDA of $98.1 million, but FY2026 guidance of $270-310 million reflects a 45-52% decline driven by CMS reimbursement policy changes for skin substitute products. The company has responded with a workforce reduction of 88 employees, closure of its St. Petersburg facility (~$14 million annualized savings), continued pipeline development including ReNu, and clinical evidence generation for PuraPly AM in diabetic foot ulcers.

Name

Organogenesis

Legal name

Organogenesis Inc.

Website

https://organogenesis.com

Company type

Public

Founded year

1985

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Organogenesis is a publicly traded regenerative medicine company developing FDA-approved skin substitutes, antimicrobial wound matrices, and amniotic allografts for chronic wound care, surgical, and sports medicine applications, sold through a direct U.S. sales force to clinicians and health systems.

Ownership category

akta.pro rank

Product category

Regenerative Medicine / Wound Care Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)

SIC

Biological Products, (No Disgnostic Substances) (2836), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

akta.pro secondary industries

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Advanced wound care products
• Regenerative medicine products
• Skin substitute therapies
• Surgical biologics solutions
• Amniotic tissue allografts

Headquarters

HQ city

Canton

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Advanced Wound Care Products: Product revenue from the company's portfolio of advanced wound care solutions including skin substitutes, wound matrices, and biologics. Major products include Apligraf, PuraPly product line, NuShield, Affinity, Novachor, CYGNUS Dual, CYGNUS Matrix, VIA Matrix, and AmchoThick. Represents the dominant revenue driver, with Q4 2025 showing $225.1M in net product revenue driven by 83% growth in Advanced Wound Care products year-over-year. Full-year 2025 Advanced Wound Care segment grew significantly but faces headwinds from CMS reimbursement policy changes in 2026.
2. Surgical and Sports Medicine Products: Revenue from surgical biologics and sports medicine products including FiberOS, OCMP, PuraPly SX, PuraPly MZ, PuraForce, and CYGNUS Matrix. Contributed to Q3 2025 record revenue growth alongside Advanced Wound Care segment.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Organogenesis manufactures and sells FDA-approved regenerative tissue products for advanced wound care (e.g., Apligraf for venous leg ulcers and diabetic foot ulcers, PuraPly antimicrobial wound matrices, placental allografts such as Novachor and Affinity) and for surgical and sports medicine applications (FiberOS, OCMP, PuraForce, PuraPly SX/MZ). The company also markets its products through a U.S. direct sales force and supports clinicians with reimbursement, customer care, and medical affairs services.

Product overview

Organogenesis is a regenerative medicine company offering a comprehensive portfolio of products for advanced wound care and surgical & sports medicine markets. The company's advanced wound care portfolio includes skin substitutes (Apligraf), antimicrobial wound matrices (PuraPly, PuraPly AM), placental allografts (Novachor, Affinity), and specialty wound matrices (NuShield, CYGNUS Dual, CYGNUS Matrix, VIA Matrix, AmchoThick). The surgical & sports medicine segment includes biologics products (PuraForce, FiberOS, OCMP, PuraPly SX, PuraPly MZ). The company also has a pipeline product, ReNu (pending FDA approval), for knee osteoarthritis treatment. Products are designed for management of chronic and acute wounds, surgical procedures, and sports medicine applications, supporting patients from early wound healing through wound closure.

Differentiator

Problem solved

Functional benefit

Brands

• PuraPly AM: Advanced wound care product - antimicrobial wound matrix
• PuraPly
• NuShield
• Affinity
• Apligraf
• Novachor
• CYGNUS Dual
• CYGNUS Matrix
• VIA Matrix
• AmchoThick
• FiberOS
• OCMP
• PuraPly SX
• PuraPly MZ
• PuraForce
• Dermagraft
• ReNu

Quantifiable outcome

• PuraPly AM achieved statistically significant wound closure at 12 weeks in diabetic foot ulcer randomized controlled trial (170 patients)
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators14 records

Recent moves9 records

Expansion highlights2 records

Direct peers

• MiMedx: MiMedx develops and markets amniotic membrane-based products (e.g., EpiFix, AmnioFix) for wound care and surgical applications, directly competing with Organogenesis's Apligraf, Affinity, Novachor, and other placental allograft products in the advanced wound care market.
• Integra LifeSciences: Integra LifeSciences offers regenerative wound care technologies including the Integra Dermal Regeneration Template and other skin substitute and wound matrix products, competing directly with Organogenesis's portfolio in chronic wound management and burn care.
• Smith+Nephew: Smith+Nephew's Advanced Wound Management division markets skin substitute products (e.g., Oasis) alongside traditional wound dressings and negative pressure wound therapy, directly overlapping with Organogenesis's wound care franchise.
• ConvaTec: ConvaTec is a global wound care company offering advanced wound dressings, skin substitutes, and ostomy products, competing with Organogenesis in chronic wound management for diabetic foot ulcers and venous leg ulcers.
• Coloplast: Coloplast's Wound & Skin Care division markets advanced wound care dressings and skin substitutes for chronic wounds, directly competing with Organogenesis in the advanced wound care market across similar patient populations.
• MTF Biologics: MTF Biologics is a nonprofit tissue bank that develops and distributes allograft-based products for wound care, orthopedics, and sports medicine, directly competing with Organogenesis's placental allograft and surgical biologic products.

Emerging players

• Bioventus: Following its acquisition of Misonix, Bioventus offers surgical biologics and wound care products (including ultrasonic wound debridement and bone healing), overlapping with Organogenesis's surgical and sports medicine franchise.

Broad incumbents

• Stryker: Stryker is a large medical device incumbent with orthopedic, surgical, and sports medicine portfolios that overlap with Organogenesis's Surgical and Sports Medicine segment, including biologic and regenerative tissue solutions.
• 3M Health Care (Solventum): 3M's Health Care business (now Solventum) provides a broad portfolio of advanced wound care products and dressings, competing with Organogenesis in hospital and outpatient wound management settings as a larger incumbent.
• Baxter International: Baxter's Medical Products & Therapies segment offers biologic products including sealants, hemostats, and regenerative tissue technologies (e.g., Tisseel, Floseal, Seprafilm) that overlap with Organogenesis's surgical biologics portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/organogenesis

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries3 records

Funding overview

Funding rounds8 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Organogenesis